Frontier Biotechnologies Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	187.6	170.34	248.98	526.66	550.89	800.85
Trading Asset Securities	542.12	542.79	600.53	415.06	690.11	679.36
Cash & Short-Term Investments	729.72	713.14	849.51	941.72	1,241	1,480
Cash Growth	-2.20%	-16.05%	-9.79%	-24.12%	-16.16%	-16.78%
Accounts Receivable	43.29	58.49	34.75	63.01	36.14	22.34
Other Receivables	134.15	133.6	227.7	2.37	10.55	1.13
Receivables	177.44	192.09	262.45	65.38	46.68	23.48
Inventory	78.2	66.62	41.06	59	55.61	38.62
Other Current Assets	302.46	32.97	69.6	36.68	62.78	35.2
Total Current Assets	1,288	1,005	1,223	1,103	1,406	1,578
Property, Plant & Equipment	417.38	423.23	393.31	793.02	728.06	605.76
Long-Term Investments	20.69	21.27	29.96	-	-	-
Other Intangible Assets	122.18	127.55	149.32	229.18	257.22	258.44
Long-Term Deferred Charges	2.04	1.44	2.03	0.94	2.74	3.12
Other Long-Term Assets	0.34	-	14.89	14.21	16.76	87.8
Total Assets	1,850	1,578	1,812	2,140	2,411	2,533
Accounts Payable	30.81	47.06	0.88	1.13	2.69	3.32
Accrued Expenses	10.63	18.52	25.11	37.39	41.84	38.98
Short-Term Debt	285.32	249.71	283.97	202.3	110.64	52.19
Current Portion of Long-Term Debt	13.53	76.33	43.01	104.06	46	227.77
Current Portion of Leases	-	-	0.23	2.4	4.42	5.09
Current Income Taxes Payable	1.15	0.93	-	-	-	-
Current Unearned Revenue	12.59	1.78	2.68	5.83	0.06	-
Other Current Liabilities	9.76	16	39.34	27.04	71.58	72.14
Total Current Liabilities	363.78	410.34	395.2	380.16	277.23	399.49
Long-Term Debt	172.51	82.86	79.36	71.42	117.12	7.5
Long-Term Leases	0.24	-	-	0.17	0.45	0.41
Long-Term Unearned Revenue	56.38	59.03	196.26	329.35	323.54	269.41
Other Long-Term Liabilities	149.26	149.21	-	16.35	21.08	25.59
Total Liabilities	742.17	701.44	670.83	797.44	739.41	702.41
Common Stock	374.58	374.58	374.58	374.58	374.58	359.76
Additional Paid-In Capital	2,731	2,727	2,723	2,723	2,723	2,540
Retained Earnings	-1,997	-2,225	-1,956	-1,755	-1,426	-1,069
Comprehensive Income & Other	0.08	0.04	0.02	0.01	0.03	-0.05
Total Common Equity	1,108	876.87	1,141	1,343	1,671	1,830
Shareholders' Equity	1,108	876.87	1,141	1,343	1,671	1,830
Total Liabilities & Equity	1,850	1,578	1,812	2,140	2,411	2,533
Total Debt	471.59	408.9	406.56	380.35	278.62	292.96
Net Cash (Debt)	258.13	304.24	442.95	561.37	962.38	1,187
Net Cash Growth	-29.29%	-31.32%	-21.09%	-41.67%	-18.94%	-32.01%
Net Cash Per Share	0.69	0.82	1.19	1.50	2.64	3.29
Filing Date Shares Outstanding	372.78	374.58	374.58	374.58	374.58	359.76
Total Common Shares Outstanding	372.78	374.58	374.58	374.58	374.58	359.76
Working Capital	924.04	594.48	827.41	722.63	1,129	1,178
Book Value Per Share	2.97	2.34	3.05	3.58	4.46	5.09
Tangible Book Value	986.1	749.32	991.99	1,114	1,414	1,572
Tangible Book Value Per Share	2.65	2.00	2.65	2.97	3.78	4.37
Buildings	-	-	159.06	76.22	76.22	-
Machinery	-	-	127.73	47.35	45.92	30.44
Construction In Progress	-	-	147.74	695.97	622.9	582.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.